STAT3 and ovarian carcinoma: Recent studies verified that abnormal activation of STAT3 signalling mediates cisplatin sensitivity in several cancers, such as breast cancer, OSCC, oesophageal squamous cell carcinoma and ovarian cancer and lung cancer40–44.